Gaudium IVF and Women Health LimitedPharmaceuticals & HealthcareGAUDIUMIVF
Q1 FY27 concall · earnings callGaudium IVF and Women Health Limited
Gaudium IVF's Q1 focused on investing ahead of its expansion roadmap, absorbing higher costs for marketing its new AI tools and new hub development while maintaining confidence in achieving its full-year growth targets.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from Operations (Q1 FY27) | ₹19.4 Cr | 9.1% | |
| EBITDA | ₹2.4 Cr | -52.96% | |
| EBITDA Margin | 12.5% | -1,651 bps | |
| PAT | ₹1.8 Cr | -42.27% | |
| Clinical Pregnancy Success Rate (First Attempt) | 62% | — |
TL;DR
- Revenue grew 9.1% YoY to ₹19.4 crores, while EBITDA and PAT moderated due to front-loaded expansion costs.
- The company opened its first new hub under IPO plans at South Extension, with two more (Gurgaon and Nagpur) to open within the next month.
- AI embryology tools SiD and ERICA are now integrated, showing an ~8% improvement in first-attempt success rates in early use.
- Management provided guidance for 30% revenue growth for FY27 and expects to sustain EBITDA margins.
- The board approved a ₹15 crore project for a women's hospital in Lucknow, to be funded from internal accruals.
Said on the call
“This moderation is a direct reflection of the investments we have consciously made ahead of our 27 hub roll out.”
From the Q&A
| Topic | What management said |
|---|---|
| Sluggish Q1 Growth | Management attributed the 9% YoY revenue growth to IVF seasonality (Q1 & Q3 are typically slow) and focus on integrating AI technology and building new hubs, expressing confidence in meeting the FY27 30% growth target. |
| Margin Pressure | The sharp decline in EBITDA margin to 12.5% was attributed to a one-time, heavy marketing push for SiD and ERICA across India, which was a front-loaded expense for expansion. |
| New Hub Economics | Average capex per new hub is ₹2.5 crores. A matured hub in a Tier 2 city is expected to do 30 cycles annually, while a metro hub could do about 50 cycles, with initial packages starting from ₹2 lakhs. |
| Expansion into Women's Hospital Business | The rationale for the Lucknow women's hospital project is to extend beyond IVF into comprehensive women's health, leveraging the city's status as a medical hub. It will be funded internally, not from IPO proceeds. |
| Average Revenue Per Patient (ARPP) | The ARPP for the quarter, excluding low-value services, is approximately ₹4 lakhs, up from the ₹3.5 lakhs figure mentioned in the investor presentation. |
| Implementation of ART Act | Ground implementation of the ART & Surrogacy Act is at various stages across states, with some states having formed boards and begun registrations, but full execution is expected to take another year or so. |
Guidance
- Guidance of 30% revenue growth year-on-year for FY27.
- Confident in sustaining EBITDA and PAT margins for FY27.
Source
Summary written from the transcript filed by Gaudium IVF and Women Health Limited for the call held on 14 Aug 2026; published 19 Aug 2026, 20:04 IST.
More Q1 FY27 concalls ·How verification works ·Report an error